Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Doug Samuelson is Chief Financial Officer at Kairos Pharma. OQRO lists 2 transactions filed with the SEC under this name, the latest on Nov 27, 2025, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
2
Companies involved
1
As of the latest filing on , Doug Samuelson reported holding 293,039 shares of Kairos Pharma (KAPA), worth about $128K at the last close of $0 (Nov 20, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Kairos Pharma KAPA | 293,039 | 293K direct | $0 | $128K | Oct 8, 2025 |
Is this Doug Samuelson’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −29.4 pts vs S&P 500, beat it 0 of 1 time.
Average −29.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 25, 2024 to Nov 25, 2024, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Kairos PharmaKAPA
2 disclosures · Nov 2024 – Nov 2025 · 1 bought
Oct 8, 2025153Kdisclosed Nov 27
DetailsOfficial recordNov 22, 2024Bought~$3.8Kdisclosed Nov 25
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Doug Samuelson bought shares on the open market in 2024, and has not bought since 2024 across 2 companies. Sales in 1 of the 4 years since 2023.
Doug Samuelson reported 1 open-market purchase and 1 sale since 2023; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $3.8K1×1 trade | — |
| 2023 | — | $31K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 8, 2025, Doug Samuelson reported holding 293,039 shares of Kairos Pharma (KAPA). At the last close of $0 on Nov 20, 2026, that is about $128K. This is the stake disclosed in filings, not a net worth.
No public filing gives Doug Samuelson's net worth. What SEC Form 4 shows is the stock stake: 293,039 shares of Kairos Pharma (KAPA), about $128K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Doug Samuelson bought shares on the open market in 2024, and has not bought since 2024 across 2 companies. Sales in 1 of the 4 years since 2023.
In SEC filings since 2023: the latest open-market purchase is from 2024; the latest open-market sale is from 2023.
2 companies: Kairos Pharma (KAPA, 2024), Genelux (GNLX, 2023).
Doug Samuelson reported 1 open-market purchase and 0 sales here, 2024.
Doug Samuelson reported 0 open-market purchases and 1 sale here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.